Analystreport

Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target lowered by analysts at UBS Group AG from $44.00 to $38.00. They now have a "buy" rating on the stock.

Celldex Therapeutics, Inc.  (CLDX) 
Last celldex therapeutics, inc. earnings: 11/12 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celldex.com